Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
This study is based on the hypothesis that stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease.
Ongoing clinical trials in the Hadassah Hospital have shown that vaccination of patients with a cell line of tumor cells from the patient himself, or with a combination of three cell lines that partially match the patient's cell characteristics, could improve the immune response against the tumor, was associated with improved disease-free and overall survival.
In this study, the investigators will evaluate the efficacy of a modified tumor cell vaccine, in terms of immune response,improved disease-free and overall survival. The vaccine consists of a cell line that has a high expression level of melanoma molecules, and has been genetically modified to induce a strong immune response.
High Risk HLA-A2+ Melanoma
Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients|
- Number of adverse effects [ Time Frame: For 20 weeks from the start of treatment ] [ Designated as safety issue: Yes ]
- Overall and disease free survival [ Time Frame: For at least five years ] [ Designated as safety issue: No ]
- Emergence of anti-tumor T cell reactivity [ Time Frame: To be measured one month after the last vaccine was admininstered, on average 18-20 weeks after treatment start ] [ Designated as safety issue: No ]
|Study Start Date:||June 2013|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
|Experimental: Melanoma vaccine||Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand|